| 1 |
33356991 | Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. | 2022 Jan |
1 |
| 2 |
34365852 | Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. | 2022 Feb |
2 |
| 3 |
34649966 | Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors. | 2022 Jan |
2 |
| 4 |
34935553 | Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer. | 2022 Apr |
1 |
| 5 |
34959152 | Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. | 2022 Feb |
1 |
| 6 |
35040682 | Ado-trastuzumab emtansine associated spider telangiectasia. | 2022 Jun |
2 |
| 7 |
35078201 | Trastuzumab Emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure? | 2022 Jan 25 |
1 |
| 8 |
35251981 | Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review. | 2022 |
1 |
| 9 |
35320644 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. | 2022 Mar 24 |
4 |
| 10 |
35448182 | Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review. | 2022 Apr 8 |
1 |
| 11 |
35544899 | Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. | 2022 |
1 |
| 12 |
32423326 | Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer. | 2021 Apr |
2 |
| 13 |
32727341 | Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review. | 2021 |
1 |
| 14 |
32917537 | Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. | 2021 Jun |
1 |
| 15 |
32920921 | The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence. | 2021 Jan |
1 |
| 16 |
33245671 | Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. | 2021 Mar |
2 |
| 17 |
33389616 | Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). | 2021 May |
3 |
| 18 |
33390481 | [Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU®)]. | 2021 |
1 |
| 19 |
33431297 | In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells. | 2021 Apr |
1 |
| 20 |
33435824 | Ado-trastuzumab emtansine: Avoiding side-effects of traditional HER2 positive breast cancer treatment. | 2021 Oct |
2 |
| 21 |
33474679 | Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer. | 2021 Apr |
1 |
| 22 |
33569405 | Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. | 2021 Jan |
1 |
| 23 |
33647599 | The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. | 2021 Apr |
3 |
| 24 |
33663447 | Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. | 2021 Mar 4 |
1 |
| 25 |
33731670 | Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer. | 2021 Mar 17 |
3 |
| 26 |
33819752 | T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. | 2021 Apr |
2 |
| 27 |
33844843 | Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. | 2021 Apr 12 |
2 |
| 28 |
33862249 | Current treatment options for HER2-positive breast cancer patients with brain metastases. | 2021 May |
1 |
| 29 |
33876415 | Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China. | 2021 Jun |
2 |
| 30 |
33937626 | Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. | 2021 Jan |
1 |
| 31 |
33992964 | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. | 2021 Aug |
2 |
| 32 |
34000917 | Trastuzumab-emtansine induced pleural and pericardial effusions. | 2021 Dec |
2 |
| 33 |
34012912 | Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. | 2021 |
1 |
| 34 |
34014777 | Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. | 2021 Jul-Aug |
1 |
| 35 |
34023398 | Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine. | 2021 Sep |
1 |
| 36 |
34057699 | How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer. | 2021 Dec |
1 |
| 37 |
34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | 2021 Jul 20 |
2 |
| 38 |
34151896 | Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States. | 2021 Jul 1 |
3 |
| 39 |
34194883 | Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis. | 2021 May 27 |
2 |
| 40 |
34213636 | Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. | 2021 Jul 2 |
1 |
| 41 |
34215870 | A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). | 2021 Aug 30 |
1 |
| 42 |
34232951 | Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report. | 2021 Nov 1 |
4 |
| 43 |
34238257 | Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). | 2021 Jul 9 |
3 |
| 44 |
34277062 | A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers. | 2021 Jun |
1 |
| 45 |
34296283 | Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). | 2021 Aug 30 |
1 |
| 46 |
34380530 | Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. | 2021 Aug 11 |
1 |
| 47 |
34479891 | Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. | 2021 Sep 3 |
1 |
| 48 |
34490125 | Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. | 2021 |
3 |
| 49 |
34522496 | A Case Report of an Emergency Hypertensive Episode During Trastuzumab Therapy. | 2021 Aug |
2 |
| 50 |
34598949 | Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer? | 2021 Oct |
2 |